32.31BMarket Cap
67.69P/E TTM
Key Figures
319.730Open
320.450High
249.96KVolume
67.69P/E TTM
29.48P/E Dynamic
--Dividend TTM
0.24%Turnover Ratio
322.080Prev. Close
311.050Low
55.28MTurnover
LossP/E Static
6.75P/B
0.00%Div Yield TTM
7.13%ROA
385.22052wk High
0.95Volume Ratio
-644.79MNet Profit
102.26MShares
4.6682EPS TTM
0.49Beta
12.33%ROE
239.25052wk Low
2.92%Amplitude
88.95%Gross Margin
32.31BMarket Cap
4.88Reward/Risk
1.68%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Beigene Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 75 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 406.96.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Beigene Ltd Highlights
StrengthsRisks
Beigene Ltd News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
25
Kymera Therapeutics Inc
KYMR
23
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Beigene Ltd Info
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Ticker SymbolONC
CompanyBeigene Ltd
CEOOyler (John Victor)
Websitehttps://beonemedicines.com/
Shareholders
FAQs
What is the current price of Beigene Ltd (ONC)?
The current price of Beigene Ltd (ONC) is 315.97.
What is the symbol of Beigene Ltd?
The ticker symbol of Beigene Ltd is ONC.
What is the 52-week high of Beigene Ltd?
The 52-week high of Beigene Ltd is 385.22.
What is the 52-week low of Beigene Ltd?
The 52-week low of Beigene Ltd is 239.25.
What is the market capitalization of Beigene Ltd?
The market capitalization of Beigene Ltd is 32.31B.
Is Beigene Ltd (ONC) currently rated as Buy, Hold, or Sell?
According to analysts, Beigene Ltd (ONC) has an overall rating of Buy, with a price target of 406.96.
What is the Earnings Per Share (EPS TTM) of Beigene Ltd (ONC)?
The Earnings Per Share (EPS TTM) of Beigene Ltd (ONC) is 2.63.
